{"id":535490,"date":"2021-03-24T20:38:02","date_gmt":"2021-03-24T20:38:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=535490"},"modified":"2021-03-24T20:38:02","modified_gmt":"2021-03-24T20:38:02","slug":"acne-vulgaris-av-market-size-and-share-epidemiology-insights-and-market-forecast-report-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acne-vulgaris-av-market-size-and-share-epidemiology-insights-and-market-forecast-report-2030-by-delveinsight_535490.html","title":{"rendered":"Acne Vulgaris (AV) Market Size and Share, Epidemiology Insights, and Market Forecast Report 2030 by DelveInsight"},"content":{"rendered":"
\"Acne<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Acne Vulgaris (AV) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acne Vulgaris (AV) , historical and forecasted epidemiology as well as the Acne Vulgaris (AV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n

DelveInsight<\/strong> launched its new report on Acne Vulgaris (AV) – Market Insights, Epidemiology, and Market Forecast-2030<\/a>.<\/strong><\/p>\n

DelveInsight’s “Acne Vulgaris (AV) Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Acne Vulgaris (AV) , historical and forecasted epidemiology as well as the Acne Vulgaris (AV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

View report: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/acne-vulgaris-av-market<\/strong><\/a><\/p>\n

Some key facts of the report:<\/strong>
1. Acne Vulgaris affects ~85% of young adults aged 12–25 years.
2. Acne vulgaris is more common in males than in females.<\/p>\n

Key benefits of the report:<\/strong>
1. In the coming years, Acne Vulgaris (AV) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
2. The companies and academics are working to assess challenges and seek opportunities that could influence Acne Vulgaris (AV) R&D. The therapies under development are focused on novel approaches to treat\/improve the disease condition       
3. Major players are involved in developing therapies for Acne Vulgaris (AV) . Launch of emerging therapies will significantly impact the Acne Vulgaris (AV) market
4. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acne Vulgaris (AV)<\/p>\n

Acne Vulgaris (AV) is a common chronic skin disease involving blockage and\/or inflammation of pilosebaceous units (hair follicles and their accompanying sebaceous gland). <\/strong><\/p>\n

Moderate-to-severe inflammatory acne is characterized by the presence of nodules and cyst.<\/strong><\/p>\n

Request for sample pages<\/strong>: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/acne-vulgaris-av-market<\/strong><\/a><\/p>\n

Key pharma players involved in Acne Vulgaris market are:<\/strong><\/p>\n

    \n
  1. Maruho<\/li>\n
  2. Boston Pharmaceuticals<\/li>\n
  3. Botanix Pharmaceuticals<\/li>\n
  4. Vyome<\/li>\n
  5. Novartis Pharmaceuticals<\/li>\n<\/ol>\n

    Drugs involved are:<\/strong><\/p>\n

      \n
    1. CLS001<\/li>\n
    2. BOS-356<\/li>\n
    3. BTX 1503<\/li>\n
    4. VB-1953<\/li>\n
    5. LYS006<\/li>\n<\/ol>\n

      Table of contents:<\/strong>
      1. Key Insights
      2. Executive Summary of Acne Vulgaris (AV)
      3. Competitive Intelligence Analysis for Acne Vulgaris (AV)
      4. Acne Vulgaris (AV): Market Overview at a Glance
      5. Acne Vulgaris (AV): Disease Background and Overview
      6. Patient Journey
      7. Acne Vulgaris (AV) Epidemiology and Patient Population
      8. Treatment Algorithm, Current Treatment, and Medical Practices
      9. Unmet Needs
      10. Key Endpoints of Acne Vulgaris (AV) Treatment
      11. Marketed Products
      12. Emerging Therapies
      13. Acne Vulgaris (AV): Seven Major Market Analysis
      14. Attribute analysis
      15. 7MM: Market Outlook
      16. Access and Reimbursement Overview of Acne Vulgaris (AV)
      17. KOL Views
      18. Market Drivers
      19. Market Barriers
      20. Appendix
      21. DelveInsight Capabilities
      22. Disclaimer
      23. About DelveInsight<\/p>\n

      Click here and get access to free sample pages of the report.<\/strong><\/span><\/a><\/p>\n

      Related reports:<\/strong><\/span><\/p>\n

      Acne Vulgaris Pipeline Insight, 2020<\/strong><\/p>\n

      Acne Vulgaris – Epidemiology Forecast to 2030<\/strong><\/p>\n

      About DelveInsight<\/strong><\/span>
      DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

      Contact us:<\/span>
      <\/strong>Shruti Thakur
      info@delveinsight.com<\/span>
      +919650213330<\/span><\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight’s “Acne Vulgaris (AV) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acne Vulgaris (AV) , historical and forecasted epidemiology as well as the Acne Vulgaris (AV) market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-535490","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/535490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=535490"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/535490\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=535490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=535490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=535490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}